Vir Biotechnology, Inc. (NASDAQ:VIR) Major Shareholder Sells $1,854,923.84 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) major shareholder Endurance (Cayman) Ltd Svf sold 69,839 shares of the business’s stock in a transaction on Thursday, January 19th. The stock was sold at an average price of $26.56, for a total transaction of $1,854,923.84. Following the completion of the sale, the insider now owns 19,527,382 shares in the company, valued at approximately $518,647,265.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

  • On Tuesday, January 17th, Endurance (Cayman) Ltd Svf sold 88,372 shares of Vir Biotechnology stock. The stock was sold at an average price of $26.24, for a total value of $2,318,881.28.
  • On Friday, January 13th, Endurance (Cayman) Ltd Svf sold 94,199 shares of Vir Biotechnology stock. The stock was sold at an average price of $26.54, for a total value of $2,500,041.46.
  • On Wednesday, January 11th, Endurance (Cayman) Ltd Svf sold 79,065 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.24, for a total value of $2,074,665.60.
  • On Monday, January 9th, Endurance (Cayman) Ltd Svf sold 34,801 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.85, for a total transaction of $899,605.85.
  • On Friday, January 6th, Endurance (Cayman) Ltd Svf sold 66,179 shares of Vir Biotechnology stock. The stock was sold at an average price of $26.13, for a total transaction of $1,729,257.27.
  • On Tuesday, January 3rd, Endurance (Cayman) Ltd Svf sold 8,177 shares of Vir Biotechnology stock. The shares were sold at an average price of $25.58, for a total transaction of $209,167.66.
  • On Tuesday, December 27th, Endurance (Cayman) Ltd Svf sold 6,850 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.59, for a total value of $175,291.50.
  • On Thursday, December 22nd, Endurance (Cayman) Ltd Svf sold 95,144 shares of Vir Biotechnology stock. The shares were sold at an average price of $26.07, for a total value of $2,480,404.08.
  • On Tuesday, December 20th, Endurance (Cayman) Ltd Svf sold 104,026 shares of Vir Biotechnology stock. The stock was sold at an average price of $25.53, for a total value of $2,655,783.78.
  • On Monday, December 5th, Endurance (Cayman) Ltd Svf sold 8,831 shares of Vir Biotechnology stock. The shares were sold at an average price of $27.25, for a total transaction of $240,644.75.

Vir Biotechnology Stock Performance

Vir Biotechnology stock traded up $1.57 during trading hours on Monday, hitting $29.16. The company had a trading volume of 1,003,586 shares, compared to its average volume of 716,180. The firm has a market cap of $3.88 billion, a P/E ratio of 3.43 and a beta of 0.15. The company has a 50-day moving average price of $26.29 and a two-hundred day moving average price of $25.06. Vir Biotechnology, Inc. has a 1 year low of $18.05 and a 1 year high of $35.48.

Vir Biotechnology (NASDAQ:VIRGet Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported $1.30 earnings per share for the quarter, beating the consensus estimate of $0.01 by $1.29. The company had revenue of $374.56 million for the quarter, compared to the consensus estimate of $153.79 million. As a group, equities research analysts anticipate that Vir Biotechnology, Inc. will post 4.61 EPS for the current year.

Institutional Investors Weigh In On Vir Biotechnology

Hedge funds have recently made changes to their positions in the company. US Bancorp DE increased its stake in shares of Vir Biotechnology by 175.1% during the second quarter. US Bancorp DE now owns 982 shares of the company’s stock valued at $25,000 after buying an additional 625 shares during the period. Nisa Investment Advisors LLC grew its holdings in Vir Biotechnology by 127.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $25,000 after acquiring an additional 560 shares in the last quarter. Wipfli Financial Advisors LLC bought a new position in Vir Biotechnology during the 3rd quarter worth about $25,000. SeaCrest Wealth Management LLC purchased a new position in Vir Biotechnology during the 2nd quarter valued at about $36,000. Finally, Captrust Financial Advisors raised its holdings in shares of Vir Biotechnology by 1,270.7% in the 2nd quarter. Captrust Financial Advisors now owns 1,823 shares of the company’s stock valued at $46,000 after purchasing an additional 1,690 shares in the last quarter. 74.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

VIR has been the subject of a number of recent analyst reports. Morgan Stanley lifted their price target on shares of Vir Biotechnology from $15.00 to $18.00 and gave the stock an “underweight” rating in a research note on Friday, November 4th. Needham & Company LLC dropped their target price on Vir Biotechnology from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Friday, November 4th. SVB Leerink increased their price target on Vir Biotechnology from $40.00 to $45.00 and gave the stock an “outperform” rating in a report on Friday, November 4th. Finally, TheStreet upgraded Vir Biotechnology from a “d” rating to a “c-” rating in a report on Monday, October 10th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $52.50.

About Vir Biotechnology

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Read More

Insider Buying and Selling by Quarter for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.